BIAL
18.2.2021 01:03:05 CET | Business Wire | Press release
Press Release for European Medical and Trade Media Only
BIAL announces the end of the licence agreement established in 2009. BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures)
For over a decade, BIAL and Eisai have had an agreement in place for Eisai to market, promote, and distribute eslicarbazepine acetate in Europe. Following the end of this partnership, BIAL will take the lead for the ongoing marketing, promotion and distribution in Europe. This move reinforces its continued commitment to and ongoing investment in neurological conditions.
BIAL has over 10 years of experience of delivering life-improving medicines for neurological conditions such as epilepsy and Parkinson’s disease. Eslicarbazepine acetate was the first medicine discovered and developed by BIAL. Epilepsy has a high prevalence with 6 million people affected in Europe and 15 million Europeans estimated to experience a seizure at some time in their life1 . Each month over 90,000 people with epilepsy around the world benefit from eslicarbazepine acetate to meet their treatment needs.
BIAL has worked closely with the relevant organisations from around Europe to put in place all the supply, quality and pharmacovigilance processes that are needed to ensure a seamless transition for both healthcare professionals and patients. All required drug safety and medicine continuity measures have been secured to ensure an uninterrupted treatment supply for all those who need it.
“Following a constructive partnership with Eisai, we are excited to be taking the lead on the commercialisation of eslicarbazepine acetate in Europe”, stated José Almeida Bastos, Chief Commercial Officer of BIAL. “It was the first medicine to be developed through BIAL’s own research and is a valuable part of our portfolio as we continue to expand into new territories, building on our established heritage and making life better for all those affected by epilepsy .”
Neil West, Vice President EMEA, Global Neurology Business Unit from Eisai, also commented, “We have enjoyed working alongside BIAL, providing our extensive commercialisation experience for the marketing and distribution of this important treatment. We believe eslicarbazepine acetate has made a real difference to patients’ lives during this period and are proud of our contribution. ”
###
About Zebinix® (eslicarbazepine acetate)
Eslicarbazepine acetate is a voltage-gated sodium channel blocker. It selectively targets the slow inactivated state of the sodium ion channel (which have been implicated in the pathogenesis of epilepsy), preventing its return to the active state, and thereby reduces repetitive neuronal firing.2,3
Zebinix® is indicated as monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy and also as adjunctive therapy in patients aged above 6 years, with partial-onset seizures with or without secondary generalisation.4
The efficacy and safety of Zebinix® when used as adjunctive therapy have been shown in clinical data from four Phase III multi-centre, randomized, double-blind, placebo-controlled trials (BIA -2093- 301, 302, 303 and 304), that included more than 1,300 patients with refractory partial-onset seizures.5-8 On the other hand, the efficacy and safety of Zebinix® as monotherapy have been demonstrated in a phase III, randomized, double-blind, noninferiority, active controlled (carbamazepine-CR) study (BIA-2093-311), involving 815 randomized adult patients with newly diagnosed partial-onset seizures.9
About Epilepsy
Around 50 million people in the world have epilepsy. It is the most common serious neurological condition.1 It affects people of all ages, sexes, races and geographical locations.10 Access to antiseizure medications offers the potential for approximately 70% of people with epilepsy to live seizure free, with an opportunity to impact their quality of life.10
Epilepsy is a neurological disorder that is characterized by an enduring predisposition to generate epileptic seizures and the associated cognitive, psychological and social consequences. An epileptic seizure is a transient behavioural change that might be objective signs or subjective symptoms caused by abnormal excessive or synchronous neuronal activity in the brain.11
The majority of people with epilepsy have a good prognosis. The prognosis is strongly influenced by the underlying cause. In many people, particularly children, the condition will remit, although a substantial proportion will have epilepsy all their lives. Overall, 60-70% of patients become seizure free after treatment with antiepileptic drugs, and some patients can remain in remission after subsequent drug withdrawal.12 The other 30-40% continue to have seizures with varying degrees of frequency and severity (refractory epilepsy).12
About BIAL
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last few decades, BIAL has focused strategically on quality, innovation and internationalisation.
BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide.
For more information on BIAL: www.bial.com
For more information on Zebinix® : https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix#product-information-section
References
1- Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe. WHO report. Available at https://www.who.int/mental_health/neurology/epilepsy/euro_report.pdf. Last Accessed January 2021
2- Hebeisen S, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology 2015; 89:122-35
3- Vilin YY; Ruben PC, Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. Cell Biochem Biophys 2001; 35:171–90
4- SmPC Zebinix® 2020, last accessed in January 2021
5- Elger C, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial onset seizures: A randomised, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009; 50:454-63
6- Ben-Menachem E, et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89(2-3):278-85
7- Gil-Nagel A, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009; 120:281-87
8- Sperling MR et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsy. 2015 56(2): 244-253
9- Trinka et al. Efficacy and safety of eslicarbazepine acetate versus controlled release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study, Epilepsia. 2018;59:479–491
10- Epilepsy: a public health imperative, World Health Organization Report 2019. Available at https://www.who.int/news-room/fact-sheets/detail/epilepsy. Last accessed January 2021
11- Devinsky, O., Vezzani, A., O'Brien, T. et al. Epilepsy. Nat Rev Dis Primers 2018 4, 18024. https://doi.org/10.1038/nrdp.2018.24
12- Brodie MJ, Kwan P, Schachter SC. Fast Facts: Epilepsy. 3rd edition. Oxford (UK): Health Press Limited; 2005
Job code ZB/FEB21/G/029
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005821/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Releases The Xsolla Report: Mobile D2C Edition28.9.2026 15:00:00 CEST | Press release
New Data From More Than 800 Mobile Web Shops Finds Direct-to-Consumer Has Become a Standard Operating Discipline, With Top Performers Capturing More Than Half of a Title's Revenue Regardless of Studio Size Xsolla, a global commerce company, today released The Xsolla Report: Mobile D2C Edition, a new study examining how direct-to-consumer commerce is performing across mobile games. Drawing on data from more than 800 live Xsolla Web Shops alongside public market and regulatory data, the report shows that D2C has moved past the question of whether it works and into a new phase: studios seeing the strongest results are the ones treating their Web Shop as an operating discipline rather than a one-time build. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928312597/en/ Graphic: Xsolla Three themes run through the report. First, the gap between a typical Web Shop and a top-performing one is wide, and closing it has little to do
Incognito Software Systems Launches NEXA, an AI-Enabled Solution for Automated Broadband Operations28.9.2026 15:00:00 CEST | Press release
NEXA unifies network, device, service, and subscriber data to help broadband service providers identify issues earlier, improve customer experience, reduce churn, and automate operations. Incognito Software Systems, a leading global provider of service orchestration, device management, and network intelligence solutions, today introduced NEXA, an AI-driven network intelligence and automation platform that enables broadband service providers to turn operational data into action. NEXA unifies network, device, service, and subscriber data in a single intelligence layer, delivering real-time and predictive insights that help service providers identify issues sooner, better understand the subscriber experience, and take faster, more informed action across their operations. As service providers seek to differentiate beyond connectivity, subscriber experience has become a critical competitive advantage. However, networks have evolved into complex service platforms that span access, edge, cust
Volante Technologies and Circle advance stablecoin payment and settlement capabilities for financial institutions28.9.2026 15:00:00 CEST | Press release
Collaboration enables banks to integrate USDC workflows within existing multi-rail payments infrastructure Volante Technologies, the global leader in Payments as a Service (PaaS), today announced a strategic collaboration with Circle Internet Group, Inc. (NYSE: CRCL) (“Circle”), a leading internet financial platform company and the issuer of USDC1 through its regulated entities, to help financial institutions integrate stablecoin payment and settlement capabilities into their existing payment operations. Through the collaboration, Volante is bringing USDC workflows into its AI-powered Payments Platform, enabling financial institutions to evaluate how stablecoin activity can operate alongside existing payment rails, operational controls, and on- and off-ramp requirements - without requiring a separate digital asset stack. Volante clients, which include four of the top five global corporate banks and seven of the top 10 U.S. banks, will be able to evaluate key workflows, including mintin
Zayed Sustainability Prize Unveils 2027 Finalists Following Record-Breaking Global Entry28.9.2026 14:47:00 CEST | Press release
Record 10,233 submissions from 177 countries, up 32% year-on-yearFinalists are delivering practical, scalable solutions across health, food, energy, water and climate actionPrize has positively impacted more than 411 million lives worldwide From AI that can predict pregnancy complications months in advance and robots that navigate water networks, to new technologies restoring degraded soil and heat-resilient corals rebuilding reefs, the Zayed Sustainability Prize has unveiled its 2027 finalists following the most competitive cycle in its history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928805335/en/ Members of the Zayed Sustainability Prize Jury gathered in Abu Dhabi to determine the 2027 winners and finalists (Photo: AETOSWire) A record 10,233 submissions from 177 countries were received for the 2027 cycle, a 32% increase year-on-year, reflecting the growing global reach of the UAE’s pioneering award for innovativ
ZincFive Expands Nickel-Zinc Technology into In-Rack Backup and AI Dynamic Power Solutions28.9.2026 14:05:00 CEST | Press release
Applying proven high-rate nickel-zinc technology to in-rack backup and AI-driven transient power applications ZincFive®, the leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced its expansion into in-rack energy storage with the development of Battery Backup Unit (BBU) and AI Dynamic Power Module (DPM) solutions designed to address the evolving energy storage requirements of AI data centers. As AI drives higher rack power densities and increasingly dynamic workloads, data center power architectures are evolving to manage both traditional backup requirements and rapid, repeated changes in power demand. These transient loads can place significant stress on electrical infrastructure, creating a growing need for power solutions closer to the rack that can respond quickly, safely, and reliably. Today’s rack-level technologies often require tradeoffs between energy capacity and dynamic power response. Traditional BBUs are primarily designed t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom